Amgen Ordered to Pay $50.3 Million for Patent Infringement in Leukemia Drug Case

In a recent legal development, Germany’s Lindis Biotech has successfully convinced a Delaware federal jury that Amgen Inc. must pay $50.3 million in damages. The verdict pertains to allegations that Amgen encouraged healthcare providers to infringe on Lindis Biotech’s immunotherapy patents by promoting the administration of their leukemia drug Blincyto. The Munich company argued that these actions violated their patent rights, leading to the substantial damages awarded by the court. For further details on this case, click here.